Posted by Michael Wonder on 07 Jun 2021
GSK’s PD-1 inhibitor Jemperli approved in the UK
7 June 2021 - GSK's PD-1 inhibitor Jemperli has been authorised by the UK MHRA for the treatment of recurrent or advanced endometrial cancer.
Specifically, Jemperli (dostarlimab) has been granted a conditional marketing authorisation for use in adult patients with mismatch repair deficient or microsatellite instability-high recurrent or advanced endometrial cancer, who have progressed on or following prior treatment with a platinum containing regimen.
